Creative Biostructure has a rich experienced scientific team focused on virus-like particles for years. Creative Biostructure has established a leading and comprehensive Mempro™ Virus-like Particles (VLPs) platform to produce custom virus-like particles for vaccine research and other applications. We are your reliable business partner in virus-like particles field to provide both the high-quality products and best services.
Recently, noninfectious VLPs has been thought to provide good potential for advanced vaccines for a broad range of viruses that cause human diseases. One of the crucial factors in VLPs production is the appropriate selection of the expression systems. Creative Biostructure can provide custom VLPs production which depended on your specific target in various expression systems, and Mempro™ Virus-like Particles (VLPs) production in mammalian cells system is one of them.
Figure 1. TEM micrographs of the VLP sample generated by mammalian cells system. (Plos One, 2010)
Mammalian cells system for VLPs production has a series of advantages. Compare with other expression systems such as egg and baculovirus-dependent systems, mammalian cells system can both increase the production flexibility and consistency and recover the native specific glycosylation properly, furthermore, this system can provide proper membrane protein folding, assembly and post-translational modifications. Creative Biostructure has developed various mammalian cell lines which are very efﬁcient to construct the complex enveloped viruses, including inﬂuenza viruses to produce hybrid VLPs on the industrial scale, including Vero, MDCK, and human 293T cells. The major drawbacks of this system are the high production cost and the potential safety concerns. We provide other expression systems for VLPs production such as bacterial cells system, yeast cells system, insect cells system, and plant cells system.
Mempro™ virus-like particles (VLPs) platform offer a series services focused on the production, application, characterization and functionalization strategies for VLPs. Please feel free to contact us for a detailed quote.
C. Y. Wu, et al. (2010). Mammalian Expression of Virus-Like Particles for Advanced Mimicry of Authentic Influenza Virus. Plos One, 5(3): e9784.
B. J. Chen, et al. (2007). Influenza virus hemagglutinin and neuraminidase, but not the matrix protein, are required for assembly and budding of plasmid-derived virus-like particles. J. Virol., 81, 7111–7123.
W. Akahata, et al. (2010). A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nature Medicine, 16: 334–338.